Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

FDA’s Burden Estimate On Biologic Naming Ignores Downstream Costs, Critics Say

Executive Summary

Costs across the US healthcare system of implementing new suffix-based nomenclature could reach into the billions, stakeholders say in requesting the Office of Management and Budget delay implementation of FDA’s final guidance on nonproprietary naming of biologics pending further analysis.


Related Content

Sandoz Tested Erelzi’s Suffix On Multiple Fronts
How To Name A Biosimilar: Amgen Persisted With Amjevita Suffix Despite FDA Doubts
Where’s The Suffix? Valeant’s Siliq Approved Without Four-Letter Identifier
GPhA Rebrands As AAM, Hopes To Change Tenor Of Drug Pricing Debate
US FDA Likely Not 'Significant', Could Be Mostly Spared From Trump's Regulation-Slashing Order
Carrots and Stick: Biopharma At The White House
Trump Order Reducing Regulation Might Imperil FDA Good Guidance Practices
Biosimilar Guidances Could Be Left Out In Cold By White House Regulatory Freeze
Biological Product Suffix Submissions Limited To 10 Candidates By US FDA
Biologic Product Naming: US FDA Sticks With Suffixes ‘Devoid Of Meaning’


Related Companies